Cytek Sees $62M Q4 Revenue, Forecasts About $201M in Full-Year 2025 Sales

Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025.

Cytek expects its total revenue for the full year 2025 to be approximately $201 million. Expected revenue for the fourth quarter of 2025 of approximately $62 million represents growth of 8% compared to the fourth quarter of 2024 and 19% compared to the third quarter of 2025.

"Our fourth quarter revenue growth over the prior year represents a meaningful acceleration of growth compared to the prior quarters in 2025 and reflects a continuation of positive trends we saw emerging in the third quarter. These trends include a continuation of strong growth in Services, Reagents and Asia Pacific instrument revenue and an improvement in instrument revenue growth in the US and EMEA1. We were particularly pleased to see a return to positive growth in our instrument sales in EMEA in the fourth quarter," said Dr. Wenbin Jiang, CEO of Cytek Biosciences. "With strong execution across our portfolio, we believe we are well positioned to deliver sustainable growth and profitability in a large flow cytometry market."

The preliminary financial results in this press release are not a comprehensive statement of Cytek's financial results for the fourth quarter and full year ended December 31, 2025, and have not been audited, reviewed or compiled by its independent registered public accounting firm. Cytek's actual revenue may differ from the estimate due to the completion of the Company's year-end closing and auditing procedures and is therefore subject to adjustment. Cytek plans to report financial results for the fourth quarter and full year ended December 31, 2025, and to provide 2026 financial guidance during its earnings call expected to be held near the end of February 2026.